This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
by Zacks Equity Research
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PRFZ
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Zacks.com featured highlights ColgatePalmolive, BigCommerce and Exact Sciences
by Zacks Equity Research
ColgatePalmolive, BigCommerce and Exact Sciences have been highlighted in this Screen of The Week article.
3 Top Earnings Acceleration Stocks Worth Buying
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are ColgatePalmolive (CL), BigCommerce (BIGC) & Exact Sciences (EXAS).
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Miromatrix Medical Inc. (MIRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 10.81% and 9,200%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session.
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $66.28 in the latest trading session, marking a +1.33% move from the prior day.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $65.41, moving +1.93% from the previous trading session.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT